| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
 |
ABSTRACT |
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Nevertheless, we report here the adaptation of a strain of multi-drug resistant P. falciparum originating in Peru to New World monkeys. The isolate designated as Peru 01–134 was received from the U.S. Naval Medical Research Center (NMRCD, Lima, Peru). The results of some of the studies conducted with this parasite in different New World monkeys are also reported.
|
MATERIALS AND METHODS |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Aotus monkeys generally were housed doubly or in some cases singly to avoid injuries caused by fighting with cage mates. Space recommendations for laboratory animals were followed as set forth in the NIH Guide for the Care and Use of Laboratory Animals. All animals were fed a diet that has been proven to provide adequate nutrition and calories in captive Aotus monkeys used in malaria-related research. Feed was free of contaminants and freshly prepared. Daily observations of the animals’ behavior, appetite, stool, and condition were recorded. All were treated as medical conditions arose by an attending veterinarian.
Anopheles freeborni (F–1 strain originally from California), Anopheles gambiae (originally from The Gambia), Anopheles quadrimaculatus (originally from southeastern United States), and Anopheles stephensi (originally from Delhi, India) were laboratory-reared and maintained at the CDC/DPD insectaries. During periods when gametocytes were present in blood, mosquitoes were allowed to feed on tranquilized monkeys as previously described.12 After feeding, mosquitoes were held in an incubator at 25°C until examined 1 week later for the presence of oocysts on their midguts.
Blood-stage parasitemia was monitored and quantified by the daily examination of thick- and thin-blood films by the method of Earle and Perez.13 Infections were terminated by treatment with various combinations of drugs as described. Drugs were administered by oral intubation.
DNA was purified by the Qiagen method from Peru 01–134 parasites collected from Aotus monkeys at various times in the adaptation process. The genes for dhfr, dhps, ert, and cytochrome b were amplified from the genome of Peru 01–134 using standard PCR methods. The amplified gene fragments were sequenced directly and in their entirety on both strands of DNA using an ABI 3130x sequencing system to determine the mutations that imparted resistance to particular drugs.
The parasites used for in vitro drug testing were cultured in RPMI 1640 medium (Gibco No. 31800) supplemented with 10% O+ human serum, 2,000 mg/L sodium bicarbonate, and 25 mM HEPES at pH 7.2.14 Additional glucose was added to a final concentration of 4 g/L.15 The parasites were cultured in 25 cm2 tissue culture flasks at 10% hematocrit in O+ red blood cells (RBCs) under an atmosphere of 5% CO2, 5% O2, and 90% N2 at 37°C.
The in vitro response of Peru 01–134 to chloroquine phosphate (Sigma Chemical Co., St. Louis, MO), quinine hydrochloride (Sigma Chemical Co.), mefloquine hydrochloride (Hoffmann-La Roche Ltd., Basel, Switzerland), and artemisinin (Aldrich Chemical Co., St. Louis, MO) was assayed for growth by uptake of 3H-hypoxanthine (MP Biomedicals, Aurora, OH).16 W2, a chloroquine-resistant clone of Indochina III/CDC, and D6, a chloroquine-sensitive clone of Sierra Leone I/CDC served as controls.17 The two clones were obtained from the Walter Reed Institute of Medical Research (WRAIR, Silver Spring, MD). The tests were conducted in duplicate. Prior to testing, cultures were adjusted to 1% parasitemia. IC50 (50% inhibitory concentration) values and correlation coefficients r were determined using commercially available software, XLfit 4 (IDBS, Guildford, U.K.).
|
RESULTS |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). The prepatent period was 28 days; the course of parasitemia was transient, and the maximum parasite count was 37,017/µL. Blood was passaged into splenectomized A. nancymaae monkey AI-1782. However, a maximum parasite count of only 10/µL developed. Blood was then passaged through 2 splenectomized A. l. griseimembra monkeys, AI-2172 and AI-2178 (Figure 1), which resulted in a complete adaptation to this host. A maximum parasite count of 372,000/µL was obtained in AI-2178, 17 days after inoculation (Figure 2). The count would likely have gone higher if it had not been controlled by treatment with chlorguanide (4 mg and 2 mg), quinine (50 mg), and chloroquine (15 mg x 2 days) during the first episode of parasitemia, and chloroquine (15 mg) plus mefloquine (20 mg) once during the second episode of recrudescent parasitemia. Gametocyte production was maintained for an extended period; mosquitoes were infected on 1 occasion.
|
|
The initial passage to an A. vociferans monkey, AI-3004, was with parasites from A. nancymaae monkey AI-1770. The prepatent period was 45 days and the maximum parasite count was 2,340/µL. The second passage (Figure 1
) to AI-2619 resulted in a maximum parasite count of 9,450/µL. It was during the next passage that the parasite began to become more adapted to splenectomized A. vociferans monkeys. AI-3003, AI-1785, and AI-3007 had maximum asexual parasite counts of 74,520, 156,000, and 25,020/µL, respectively. The next passage to AI-3006 resulted in an initial maximum parasite count of 76,000/µL followed by recrudescent peak parasite counts of 29,160 and 96,000/µL. Passage from this animal to T-1201 resulted in a maximum parasite count of 236,000/µL, indicating adaptation was essentially complete. However, in none of the splenectomized animals was an infection considered to be life-threatening.
A. vociferans monkey AI-3006 had a long-term chronic infection that lasted > 300 days (Figure 3). At day 133, it was reinoculated with frozen parasites taken earlier from its own infection. A marked increase in asexual parasite count occurred that was controlled with a combination of 8 mg of chlorquanide given over 3 days followed by 50 mg of quinine. After recrudescence, the infection was treated with a single dose of malarone (31.25 mg atovoquone + 12.5 mg proguanil). A recrudescence occurred that was confirmed after 49 days. The infection was retreated on 2 successive days with malarone (62.5 mg atovoquone + 25 mg proguanil). A recrudescence occurred 11 days later. The animal was then treated on 3 successive days with malarone (93.75 mg atovoquone + 37.5 mg proguanil), which appeared to have cured the infection.
|
), the parasite was introduced into A. nancymaae monkey T-0865, which had a maximum parasite count of 320,000/µL. The animal (Figure 4) was treated with malarone (62.5 mg atovoquone + 25 mg proguanil) given over 2 days on 4 different occasions. The infection was eventually treated with 20 mg of mefloquine, which appeared to have effected a cure.
|
|
As shown in Figure 2 of the infection in A. l. griseimembra monkey AI-2178, treatment with 30 mg chloroquine and quinine temporarily cleared the primary parasitemia, but recrudescence occurred. The animal was then treated with a combination of 15 mg of chloroquine and 20 mg of mefloquine, which resulted in clearance for only a single day. The animal eventually cleared parasites on its own. However, other animals were cured by treatment with 20 mg of mefloquine. Thus, it appeared advisable to retreat the animals again with 20 mg of mefloquine 2 weeks after the first treatment to ensure cure.
Mutations in the dhfr, dhps, crt, and cytochrome b genes were analyzed from parasite isolations from Aotus AI-2171 (the first monkey passage) on March 20, 2001. Subsequent samplings for analyses were from AI-2178 (June 6, 2002), AI-3006 (December 26, 2002), AI-3006 (July 15, 2003), AI-2003 (August 12, 2003), T-865 (May 18, 2004), and T-1422 (April 8, 2004). The mutations found in the targeted genes were identical whether analysis was conducted on DNA from the first animal passage or collected much later post-drug treatment.
The dhfr gene had nonsynonymous mutations at codons 51, 108, and 164 that confer drug resistance, producing amino changes that correspond to N51I, S108N, and I164L. The Bolivian repeat sequence was also present. The dhps gene had mutations in codons 437, 540, and 581. The gene encoding the CQ-resistance transporter, crt, had the canonical CQ resistance-conferring mutation IA codon that changes K to T. The Peru 01–134 crt mutations were typical for South American isolates having the sequence SVMNT. The sequence of the cytochrome b gene was the same as the wild type.
Mosquitoes were fed on 8 different monkeys. Only A. l. griseimembra and A. vociferans were shown to produce infectious gametocytes; highest-level infections were obtained from A. vociferans monkeys AI-3003 and AI-2619. Of 2,253 An. freeborni dissected and examined, 279 were positive for oocysts (12.4%); 17.5% of An. stephensi were positive, 6.1% of An. gambiae were positive, and 15.7% of An. quadrimaculatus were positive. However, An. freeborni were more often fed on days when infection was less likely to occur. In general, this parasite readily produced gametocytes infective to standard laboratory vectors.
Drug sensitivity testing showed that the in vitro responses of the Peru 01–134 isolate of P. falciparum were comparable to those of the W2 clone for chloroquine and quinine; the IC50 values (Table 2) indicate that Peru 01–134 is resistant to both these antimalarials. Additionally, Peru 01–134 appears to be slightly more sensitive to mefloquine than does W2 but shows a similar degree of sensitivity to artimisinin.
|
|
DISCUSSION |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
20% greater than the standard total curative pediatric dosage (50 mg/kg proguanil). Giving upward of 94 mg of atovaquone and 37.5 mg of proguanil was needed to cure infection. In addition, it appeared to be less responsive to mefloquine, but this will require further testing to be sure. The R-1 level of resistance to CQ is not surprising given the crt gene of the Peru 01–134 isolate has the K-T marker for CQ resistance. However, there was also a possible low level of resistance to MQ. This will require more in vivo and in vitro testing to confirm as well as determining mutations and copy number for mdr-1 of Peru 01–134. The demonstrated resistance to malarone (atovaquone + proguanil) as well as chlorguanide is predicted by the presence of 3 mutations in dhfr and 3 others in dhps, but most relevant is the I164L mutation in dhfr that confers resistance to proguanil and chlorguanide. In splenectomized monkeys, gametocytemia was maintained and standard laboratory vectors were infected. Continued adaptation of new isolates from different endemic areas is hampered by the lack of access to A. l. griseimembra monkeys. Limited numbers are needed for the initial adaptation before subsequent passage to the available A. nancymaae and A. vociferans animals. Current laboratory-bred stocks are not adequate for the needs. However, continued isolation of emerging drug-resistant P. falciparum parasite lines is important for drug screening and development as well as vaccine evaluation.
Received March 23, 2007. Accepted for publication April 18, 2007.
Acknowledgments: The authors thank the staff of the Animal Resources Branch, National Center for Preparedness, Detection and Control of Infectious Diseases, for the care of the animals.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Financial support: This study was supported in part by an Interagency Agreement 936–3100–AA6–P–00–0006–07 between the United States Agency for International Development and the Centers for Disease Control and Prevention. Aliquots of the Peru 01–134/CDC strain of P. falciparum have been deposited with the American Type Culture Collection.
* Address correspondence to William E. Collins, Mail Stop F–36, Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee, GA 30341. E-mail: wec1{at}cdc.gov 
Authors’ addresses: W. E. Collins, J. S. Sullivan, Patrice Hall, K. K. Grady, D. Nace, Curtis Huber, J. W. Barnwell, and J. J. Sullivan, Mail Stop F-36, Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee, GA 30341, E-mail: wec1{at}cdc.gov. Trenton K. Ruebush II, USAID Bureau for Global Health, 1300 Pennsylvania Avenue, NW, Washington, DC 20523. A. Williams and G. G. Galland, Animal Resources Branch, National Center for Preparedness, Detection and Control of Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333. A. Bounngaseng and T. Williams, Atlanta Research and Education Foundation, 1670 Clairmont Road, Decatur, GA 30033.
|
REFERENCES |
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  N. Obaldia III, W. Milhous, and D. Kyle Adaptation of a Thai Multidrug-Resistant C2A Clone of Plasmodium falciparum to Aotus Monkeys and Its Preliminary in vivo Antimalarial Drug Efficacy-Resistance Profile Am J Trop Med Hyg, October 1, 2009; 81(4): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Wong, M. Connole, J. S. Sullivan, H. Choe, A. Carville, and M. Farzan A New World Primate Deficient in Tetherin-Mediated Restriction of Human Immunodeficiency Virus Type 1 J. Virol., September 1, 2009; 83(17): 8771 - 8780. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
